^
Association details:
| Biomarker: | ALK positive |
|---|---|
| Cancer: | T Cell Non-Hodgkin Lymphoma |
| Drug: | Alunbrig (brigatinib) (EGFR inhibitor, ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
RIGATINIB IN PATIENTS WITH ALK-POSITIVE ANAPLASTIC LARGE CELLLYMPHOMA WHO HAVE FAILED BRENTUXIMAB VEDOTIN
Published date:
05/11/2023
Excerpt:
ALCL was refractory to the last treatment in 10/15 pts. 10/11 pts had detectable ALK transcript in blood by RT-PCR. Pts received brigatinib at a dose of 180 mg once daily….Brigatinib showed high efficacy, including in pts who have failed crizotinib, and was well tolerated.
